CoChat

Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential

Kounatidis, Dimitris, Dalamaga, Maria, Grivakou, Eugenia, Karampela, Irene, Koufopoulos, Petros, Dalopoulos, Vasileios, Adamidis, Nikolaos, Mylona, Eleni, Kaziani, Aikaterini, Vallianou, Natalia G. · 2024 · Biomolecules
Cited by 64

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Tetracyclines constitute a unique class of antibiotic agents, widely prescribed for both community and hospital infections due to their broad spectrum of activity. Acting by disrupting protein synthesis through tight binding to the 30S ribosomal subunit, their interference is typically reversible, rendering them bacteriostatic in action. Resistance to tetracyclines has primarily been associated with changes in pump efflux or ribosomal protection mechanisms. To address this challenge, tetracycline molecules have been chemically modified, resulting in the development of third-generation tetracyclines. These novel tetracyclines offer significant advantages in treating infections, whether used alone or in combination therapies, especially in hospital settings. Beyond their conventional antimicrobial properties, research has highlighted their potential non-antibiotic properties, including their impact on immunomodulation and malignancy. This review will focus on third-generation tetracyclines, namely tigecycline, eravacycline, and omadacycline. We will delve into their mechanisms of action and resistance, while also evaluating their pros and cons over time. Additionally, we will explore their therapeutic potential, analyzing their primary indications of prescription, potential future uses, and non-antibiotic features. This review aims to provide valuable insights into the clinical applications of third-generation tetracyclines, thereby enhancing understanding and guiding optimal clinical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom14070783

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 158

  1. Nelson, 2011, The history of the tetracyclines, Ann. N. Y. Acad. Sci., 1241, 17, 10.1111/j.1749-6632.2011.06354.x · DOI · Paper page
  2. Linsell, 1950, Laboratory and clinical experience with terramycin hydrochloride, Br. Med. J., 2, 1190, 10.1136/bmj.2.4690.1190 · doi:10.1136/bmj.2.4690.1190
  3. Roberts, 2003, Tetracycline therapy: Update, Clin. Infect. Dis., 36, 462, 10.1086/367622 · DOI · Paper page
  4. Miell, 2015, Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: A systematic review, Int. J. Clin. Pract., 69, 1396, 10.1111/ijcp.12713 · doi:10.1111/ijcp.12713
  5. 2020, Doxycycline, an Antibiotic or an Anti-Inflammatory Agent? The Most Common Uses in Dermatology, Actas Dermosifiliogr. (Engl. Ed.), 111, 561
  6. Singh, 2021, Minocycline and Doxycycline: More than Antibiotics, Curr. Mol. Pharmacol., 14, 1046, 10.2174/1874467214666210210122628 · DOI
  7. Rassouli, 2023, The immunomodulatory effect of minocycline on gene expression of inflammation related cytokines in lipopolysaccharide-treated human peripheral blood mononuclear cells, Anim. Biotechnol., 34, 2159, 10.1080/10495398.2022.2077743 · DOI
  8. Jung, 2023, Clinically Approved Antibiotics from 2010 to 2022, Chimia, 77, 230, 10.2533/chimia.2023.230 · DOI
  9. Fuoco, 2012, Classification Framework and Chemical Biology of Tetracycline Structure-Based Drugs, Antibiotics, 1, 1, 10.3390/antibiotics1010001 · DOI · Paper page
  10. Barrenechea, V., Vargas-Reyes, M., Quiliano, M., and Milón, P. (2021). A Complementary Mechanism of Bacterial mRNA Translation Inhibition by Tetracyclines. Front. Microbiol., 12. · DOI · Paper page
  11. LaPlante, 2022, Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance, Ann. Med., 54, 1686, 10.1080/07853890.2022.2085881 · DOI
  12. Greer, 2006, Tigecycline (Tygacil): The first in the glycylcycline class of antibiotics, Proc. Bayl. Univ. Med. Cent., 19, 155, 10.1080/08998280.2006.11928154 · doi:10.1080/08998280.2006.11928154
  13. Zhanel, 2016, Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent, Drugs, 76, 567, 10.1007/s40265-016-0545-8 · DOI · Paper page
  14. Zhanel, 2020, Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent, Drugs, 80, 285, 10.1007/s40265-020-01257-4 · DOI
  15. Zhanel, 2004, The glycylcyclines: A comparative review with the tetracyclines, Drugs, 64, 63, 10.2165/00003495-200464010-00005 · DOI · Paper page
  16. Alegun, O., Pandeya, A., Cui, J., Ojo, I., and Wei, Y. (2021). Donnan Potential across the Outer Membrane of Gram-Negative Bacteria and Its Effect on the Permeability of Antibiotics. Antibiotics, 10. · DOI
  17. Prajapati, 2021, How to Enter a Bacterium: Bacterial Porins and the Permeation of Antibiotics, Chem. Rev., 121, 5158, 10.1021/acs.chemrev.0c01213 · DOI · Paper page
  18. Olson, 2006, Functional, biophysical, and structural bases for antibacterial activity of tigecycline, Antimicrob. Agents Chemother., 50, 2156, 10.1128/AAC.01499-05 · DOI · Paper page
  19. Stein, 2013, Tigecycline: An update, Diagn. Microbiol. Infect. Dis., 75, 331, 10.1016/j.diagmicrobio.2012.12.004 · DOI · Paper page
  20. Draper, 2014, Mechanism of action of the novel aminomethylcycline antibiotic omadacycline, Antimicrob. Agents Chemother., 58, 1279, 10.1128/AAC.01066-13 · DOI · Paper page
  21. Meagher, 2005, The pharmacokinetic and pharmacodynamic profile of tigecycline, Clin. Infect. Dis., 41, S333, 10.1086/431674 · DOI · Paper page
  22. Barbour, 2009, Clinical pharmacokinetics and pharmacodynamics of tigecycline, Clin. Pharmacokinet., 48, 575, 10.2165/11317100-000000000-00000 · DOI
  23. Zhou, 2022, Population Pharmacokinetics of Tigecycline: A Systematic Review, Drug Des. Devel. Ther., 16, 1885, 10.2147/DDDT.S365512 · doi:10.2147/dddt.s365512
  24. Li, 2020, Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment, J. Chemother., 32, 420, 10.1080/1120009X.2020.1800318 · DOI
  25. Rafailidis, P., Panagopoulos, P., Koutserimpas, C., and Samonis, G. (2024). Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections. Antibiotics, 13. · DOI
  26. McCarthy, 2019, Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline, Clin. Pharmacokinet., 58, 1149, 10.1007/s40262-019-00767-z · DOI
  27. Zou, 2023, Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study, Infect. Drug Resist., 16, 2271, 10.2147/IDR.S396910 · DOI
  28. Scott, 2019, Eravacycline: A Review in Complicated Intra-Abdominal Infections, Drugs, 79, 315, 10.1007/s40265-019-01067-3 · DOI · Paper page
  29. Rodvold, 2019, Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline, Clin. Infect. Dis., 69, S16, 10.1093/cid/ciz309 · doi:10.1093/cid/ciz309
  30. Rodvold, 2020, Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics, Clin. Pharmacokinet., 59, 409, 10.1007/s40262-019-00843-4 · DOI
  31. Trang, 2023, Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics, Antimicrob. Agents Chemother., 67, e0239721, 10.1128/aac.02397-21 · doi:10.1128/aac.02397-21
  32. Cilloniz, 2023, The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP), Expert Opin. Drug Metab. Toxicol., 19, 569, 10.1080/17425255.2023.2261376 · DOI
  33. Yaghoubi, 2022, Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review, Eur. J. Clin. Microbiol. Infect. Dis., 41, 1003, 10.1007/s10096-020-04121-1 · DOI · Paper page
  34. Betriu, 2005, In vitro activity of tigecycline against Bacteroides species, J. Antimicrob. Chemother., 56, 349, 10.1093/jac/dki197 · doi:10.1093/jac/dki197
  35. Luna, 2006, Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain, Int. J. Antimicrob. Agents, 28, 532, 10.1016/j.ijantimicag.2006.07.010 · doi:10.1016/j.ijantimicag.2006.07.010
  36. Kechagias, 2020, Tigecycline for the treatment of patients with Clostridium difficile infection: An update of the clinical evidence, Eur. J. Clin. Microbiol. Infect. Dis., 39, 1053, 10.1007/s10096-019-03756-z · DOI
  37. Zhang, T., Du, J., Dong, L., Wang, F., Zhao, L., Jia, J., Wang, C., Cheng, M., Yu, X., and Huang, H. (2023). In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria. Microbiol. Spectr., 11. · doi:10.1128/spectrum.03238-22
  38. Morrissey, 2020, In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017, Antimicrob. Agents Chemother., 64, e01699-19, 10.1128/AAC.01699-19 · DOI
  39. Zeng, W., Zhang, X., Liu, Y., Zhang, Y., Xu, M., Wang, S., Sun, Y., Zhou, T., and Chen, L. (2022). In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates. Front. Microbiol., 13. · DOI
  40. Brauncajs, M., Bielec, F., Macieja, A., and Pastuszak-Lewandoska, D. (2023). In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland. Biomedicines, 11. · doi:10.3390/biomedicines11071784
  41. Alosaimy, S., Morrisette, T., Lagnf, A.M., Rojas, L.M., King, M.A., Pullinger, B.M., Hobbs, A.L.V., Perkins, N.B., Veve, M.P., and Bouchard, J. (2022). Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol. Spectr., 10. · DOI · Paper page
  42. Alexander, 2024, A Retrospective Case-Control Study of Eravacycline for the Treatment of Carbapenem-Resistant Acinetobacter Infections in Patients With Burn Injuries, J. Burn Care Res., 45, 487, 10.1093/jbcr/irad183 · doi:10.1093/jbcr/irad183
  43. Wu, 2023, In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas maltophilia, Infect. Drug Resist., 16, 6005, 10.2147/IDR.S425061 · DOI
  44. Hawser, 2023, In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020, J. Glob. Antimicrob. Resist., 33, 304, 10.1016/j.jgar.2023.04.017 · doi:10.1016/j.jgar.2023.04.017
  45. Karlowsky, 2019, Microbiology and Preclinical Review of Omadacycline, Clin. Infect. Dis., 69, S6, 10.1093/cid/ciz395 · doi:10.1093/cid/ciz395
  46. Pfaller, 2020, Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018, Antimicrob. Agents Chemother., 64, e02488-19, 10.1128/AAC.02488-19 · DOI · Paper page
  47. Abbey, T., Vialichka, A., Jurkovic, M., Biagi, M., and Wenzler, E. (2022). Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility. Microbiol. Spectr., 10. · doi:10.1128/spectrum.00542-22
  48. Deolankar, M.S., Carr, R.A., Fliorent, R., Roh, S., Fraimow, H., and Carabetta, V.J. (2022). Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates. Antibiotics, 11. · DOI
  49. Putra, 2022, Effect of omadacycline alone and in combination with meropenem against carbapenem-resistant Acinetobacter baumannii isolates, J. Glob. Antimicrob. Resist., 29, 147, 10.1016/j.jgar.2022.03.006 · doi:10.1016/j.jgar.2022.03.006
  50. Grossman, 2016, Tetracycline Antibiotics and Resistance, Cold Spring Harb. Perspect. Med., 6, a025387, 10.1101/cshperspect.a025387 · DOI · Paper page
  51. Vanbaelen, T., Manoharan-Basil, S.S., and Kenyon, C. (2024). 45 years of tetracycline post exposure prophylaxis for STIs and the risk of tetracycline resistance: A systematic review and meta-analysis. BMC Infect. Dis., 24. · DOI
  52. Jensen, 2024, Antimicrobial treatment and resistance in sexually transmitted bacterial infections, Nat. Rev. Microbiol., 22, 435, 10.1038/s41579-024-01023-3 · DOI
  53. Sun, C., Yu, Y., and Hua, X. (2023). Resistance mechanisms of tigecycline in Acinetobacter baumannii. Front. Cell. Infect. Microbiol., 13. · DOI
  54. Roch, 2023, Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside, Clin. Microbiol. Infect., 29, 320, 10.1016/j.cmi.2022.10.018 · DOI · Paper page
  55. Khlaif, 2022, Sequencing analysis of tigecycline resistance among non-susceptible in three species of G-ve bacteria isolated from clinical specimens in Baghdad, Mol. Biol. Rep., 49, 11811, 10.1007/s11033-022-07997-8 · DOI
  56. Sun, 2021, In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis, Ann. Lab. Med., 41, 293, 10.3343/alm.2021.41.3.293 · DOI
  57. Okada, U., and Murakami, S. (2022). Structural and functional characteristics of the tripartite ABC transporter. Microbiology, 168. · DOI
  58. Dong, 2022, Distribution and spread of the mobilized RND efflux pump gene cluster tmexCD-toprJ in clinical Gram-negative bacteria: A molecular epidemiological study, Lancet Microbe, 3, e846, 10.1016/S2666-5247(22)00221-X · DOI
  59. Burata, O.E., Yeh, T.J., Macdonald, C.B., and Stockbridge, R.B. (2022). Still rocking in the structural era: A molecular overview of the small multidrug resistance (SMR) transporter family. J. Biol. Chem., 298. · DOI
  60. Shi, 2020, Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC, Infect. Genet. Evol., 80, 104185, 10.1016/j.meegid.2020.104185 · DOI
  61. Anyanwu, M.U., Nwobi, O.C., Okpala, C.O.R., and Ezeonu, I.M. (2022). Mobile Tigecycline Resistance: An Emerging Health Catastrophe Requiring Urgent One Health Global Intervention. Front. Microbiol., 13. · DOI
  62. Sun, 2019, Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli, Nat. Microbiol., 4, 1457, 10.1038/s41564-019-0496-4 · DOI · Paper page
  63. Li, 2022, Phenotypic and genomic analysis reveals Riemerella anatipestifer as the potential reservoir of tet(X) variants, J. Antimicrob. Chemother., 77, 374, 10.1093/jac/dkab409 · DOI
  64. Hsieh, Y.C., Wu, J.W., Chen, Y.Y., Quyen, T.L.T., Liao, W.C., Li, S.W., Chen, Y.C., and Pan, Y.J. (2021). An Outbreak of tet(X6)-Carrying Tigecycline-Resistant Acinetobacter baumannii Isolates with a New Capsular Type at a Hospital in Taiwan. Antibiotics, 10. · DOI
  65. Wang, Q., Lei, C., Cheng, H., Yang, X., Huang, Z., Chen, X., Ju, Z., Zhang, H., and Wang, H. (2022). Widespread Dissemination of Plasmid-Mediated Tigecycline Resistance Gene tet(X4) in Enterobacterales of Porcine Origin. Microbiol. Spectr., 10. · doi:10.1128/spectrum.01615-22
  66. Chirabhundhu, 2024, Occurrence and mechanisms of tigecycline resistance in carbapenem- and colistin-resistant Klebsiella pneumoniae in Thailand, Sci. Rep., 14, 5215, 10.1038/s41598-024-55705-2 · DOI
  67. Alosaimy, 2020, Evaluation of Eravacycline: A Novel Fluorocycline, Pharmacotherapy, 40, 221, 10.1002/phar.2366 · DOI · Paper page
  68. Hua, 2021, Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf, Emerg. Microbes Infect., 10, 1404, 10.1080/22221751.2021.1948804 · DOI
  69. Heidrich, C.G., Mitova, S., Schedlbauer, A., Connell, S.R., Fucini, P., Steenbergen, J.N., and Berens, C. (2016). The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome. Antibiotics, 5. · DOI
  70. Shi, J., Cheng, J., Liu, S., Zhu, Y., and Zhu, M. (2024). Acinetobacter baumannii: An evolving and cunning opponent. Front. Microbiol., 15. · DOI
  71. Park, S., Kim, H., and Ko, K.S. (2023). Reduced virulence in tigecycline-resistant Klebsiella pneumoniae caused by overexpression of ompR and down-regulation of ompK35. J. Biomed. Sci., 30. · DOI
  72. Xu, C., Wei, X., Jin, Y., Bai, F., Cheng, Z., Chen, S., Pan, X., and Wu, W. (2022). Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies. Microbiol. Spectr., 10. · doi:10.1128/spectrum.01390-22
  73. Ajiboye, 2018, Contributions of RecA and RecBCD DNA repair pathways to the oxidative stress response and sensitivity of Acinetobacter baumannii to antibiotics, Int. J. Antimicrob. Agents, 52, 629, 10.1016/j.ijantimicag.2018.07.022 · DOI
  74. Babinchak, 2005, The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data, Clin. Infect. Dis., 41, S354, 10.1086/431676 · DOI · Paper page
  75. Babinchak, 2005, The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam, Clin. Infect. Dis., 41, S341, 10.1086/431675 · DOI · Paper page
  76. Tanaseanu, 2008, Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia, Diagn. Microbiol. Infect. Dis., 61, 329, 10.1016/j.diagmicrobio.2008.04.009 · DOI
  77. Solomkin, 2017, Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial, JAMA Surg., 152, 224, 10.1001/jamasurg.2016.4237 · DOI · Paper page
  78. Solomkin, 2019, IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections, Clin. Infect. Dis., 69, 921, 10.1093/cid/ciy1029 · DOI · Paper page
  79. Meng, R., Guan, X., Sun, L., Fei, Z., Li, Y., Luo, M., Ma, A., and Li, H. (2022). The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis. Front. Med., 9. · DOI
  80. Lan, S.H., Chang, S.P., Lai, C.C., Lu, L.C., and Chao, C.M. (2019). The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 8. · DOI
  81. Rodriguez, G.D., Warren, N., Yashayev, R., Chitra, S., Amodio-Groton, M., and Wright, K. (2023). Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: A post-hoc analysis of the phase 3 OPTIC trial. Front. Med., 10. · doi:10.3389/fmed.2023.1225710
  82. Esposito, 2017, Italian Society of Infectious and Tropical Diseases. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: An update, J. Chemother., 29, 197, 10.1080/1120009X.2017.1311398 · DOI · Paper page
  83. Alsaad, 2014, Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis, Eur. Respir. J., 43, 884, 10.1183/09031936.00113713 · DOI
  84. Daley, 2020, Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline, Eur. Respir. J., 56, 2000535, 10.1183/13993003.00535-2020 · DOI · Paper page
  85. Kwon, 2019, Efficacy and safety of tigecycline for Mycobacterium abscessus disease, Respir. Med., 158, 89, 10.1016/j.rmed.2019.10.006 · doi:10.1016/j.rmed.2019.10.006
  86. Kaushik, 2019, In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus, Antimicrob. Agents Chemother., 63, e00470-19, 10.1128/AAC.00470-19 · doi:10.1128/aac.00470-19
  87. Wallace, 2022, In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria, Antimicrob. Agents Chemother., 66, e0068922, 10.1128/aac.00689-22 · DOI
  88. Rizzo, A.R., and Moniri, N.H. (2022). Omadacycline for management of Mycobacterium abscessus infections: A review of its effectiveness, place in therapy, and considerations for use. BMC Infect. Dis., 22. · doi:10.1186/s12879-022-07857-7
  89. Morrisette, 2023, Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: A retrospective, multicenter cohort of real-world health outcomes, Antimicrob. Agents Chemother., 67, e0082423, 10.1128/aac.00824-23 · DOI
  90. Singh, 2024, Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model, Antimicrob. Agents Chemother., 68, e0108023, 10.1128/aac.01080-23 · doi:10.1128/aac.01080-23
  91. Jump, 2011, Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production, Antimicrob. Agents Chemother., 55, 546, 10.1128/AAC.00839-10 · DOI · Paper page
  92. Phillips, 2022, Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study, Antimicrob. Agents Chemother., 66, e0000122, 10.1128/aac.00001-22 · DOI
  93. Buckley, 2021, Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model, J. Antimicrob. Chemother., 76, 171, 10.1093/jac/dkaa386 · DOI
  94. Begum, 2020, In vitro activity of eravacycline against common ribotypes of Clostridioides difficile, J. Antimicrob. Chemother., 75, 2879, 10.1093/jac/dkaa289 · DOI
  95. Skinner, 2023, Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials, J. Antimicrob. Chemother., 78, 1779, 10.1093/jac/dkad170 · DOI
  96. Budi, 2023, Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model, J. Infect. Dis., 227, 622, 10.1093/infdis/jiac324 · DOI
  97. Jo, 2024, Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers, J. Infect. Dis., 229, 273, 10.1093/infdis/jiad537 · DOI
  98. Yang, 2010, In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007, Eur. J. Clin. Microbiol. Infect. Dis., 29, 1369, 10.1007/s10096-010-1009-9 · doi:10.1007/s10096-010-1009-9
  99. Monno, R., Fumarola, L., Capolongo, C., Calia, C., Pazzani, C., Ierardi, E., and Miragliotta, G. (2015). Susceptibility of Helicobacter pylori to Antibiotics Including Tigecycline. J. Med. Microbiol. Diagn., S5. · doi:10.4172/2161-0703.s5-005
  100. Yang, Y., Bian, L., Hang, X., Yan, C., Huang, Y., Ye, F., Zhang, G., Jin, G., and Bi, H. (2020). In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China. Diagn. Microbiol. Infect. Dis., 98. · DOI
  101. Wu, 2014, Role of Tigecycline for the Treatment of Urinary Tract Infections, J. Pharm. Technol., 30, 87, 10.1177/8755122513519332 · DOI
  102. Liu, 2021, Efficacy and safety of tigecycline for complicated urinary tract infection: A systematic review, Transl. Androl. Urol., 10, 292, 10.21037/tau-20-959 · doi:10.21037/tau-20-959
  103. Charles, 2022, Role of tigecycline in the treatment of urinary tract infections: A systematic review of published case reports, InfezMed, 30, 516
  104. Stone, T.J., Kilic, A., Williamson, J.C., and Palavecino, E.L. (2023). In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates. Antibiotics, 12. · DOI
  105. Kim, 2022, Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease, Antimicrob. Agents Chemother., 66, e0077422, 10.1128/aac.00774-22 · doi:10.1128/aac.00774-22
  106. Karau, 2022, Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis, Antimicrob. Agents Chemother., 66, e0170321, 10.1128/AAC.01703-21 · doi:10.1128/aac.01703-21
  107. Morrisette, 2023, Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacokinetic/Pharmacodynamic Biofilm Model, Antimicrob. Agents Chemother., 67, e0131722, 10.1128/aac.01317-22 · DOI
  108. Ni, 2021, In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae, J. Antimicrob. Chemother., 76, 2097, 10.1093/jac/dkab122 · DOI
  109. Nulsopapon, P., Nasomsong, W., Pongchaidecha, M., Changpradub, D., Juntanawiwat, P., and Santimaleeworagun, W. (2021). The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates. Antibiotics, 10. · DOI
  110. Zavascki, 2017, Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: The pitfalls of aminoglycoside susceptibility, Expert Rev. Anti. Infect. Ther., 15, 519, 10.1080/14787210.2017.1316193 · doi:10.1080/14787210.2017.1316193
  111. Yang, 2022, Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against Klebsiella pneumoniae, Microb. Drug Resist., 28, 229, 10.1089/mdr.2021.0228 · doi:10.1089/mdr.2021.0228
  112. Rahul, R., Maheswary, D., Damodaran, N., and Leela, K.V. (2023). Eravacycline -Synergistic activity with other antimicrobials in carbapenem resistant isolates of Escherichia coli and Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis., 107. · doi:10.1016/j.diagmicrobio.2023.116006
  113. Li, 2019, Efficacy of tigecycline monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii sequence type 2 in Heilongjiang Province, Ann. Palliat. Med., 8, 651, 10.21037/apm.2019.11.06 · doi:10.21037/apm.2019.11.06
  114. Ozger, 2019, In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates, J. Antibiot., 72, 600, 10.1038/s41429-019-0188-6 · DOI
  115. Li, 2022, Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii, J. Glob. Antimicrob. Resist., 30, 56, 10.1016/j.jgar.2022.05.020 · doi:10.1016/j.jgar.2022.05.020
  116. Bich Hanh, B.T., Quang, N.T., Park, Y., Heo, B.E., Jeon, S., Park, J.W., and Jang, J. (2021). Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus. Front. Pharmacol., 12. · doi:10.3389/fphar.2021.790767
  117. Fujiwara, 2023, In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus, Antimicrob. Agents Chemother., 67, e0157922, 10.1128/aac.01579-22 · doi:10.1128/aac.01579-22
  118. Rimal, 2023, Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease, mSphere, 8, e0066522, 10.1128/msphere.00665-22 · DOI
  119. Aziz, D.B., Teo, J.W.P., Dartois, V., and Dick, T. (2018). Teicoplanin—Tigecycline Combination Shows Synergy Against Mycobacterium abscessus. Front. Microbiol., 9. · DOI
  120. Chew, K.L., Octavia, S., Yeoh, S.F., and Teo, J.W.P. (2021). In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex. Microbiol. Spectr., 9. · doi:10.1128/spectrum.00045-21
  121. Ku, 2010, Susceptibility of Candida albicans biofilms to azithromycin, tigecycline and vancomycin and the interaction between tigecycline and antifungals, Int. J. Antimicrob. Agents, 36, 441, 10.1016/j.ijantimicag.2010.06.034 · DOI
  122. Hooper, 2019, In vitro synergy with fluconazole plus doxycycline or tigecycline against clinical Candida glabrata isolates, Med. Mycol., 57, 122, 10.1093/mmy/myy008 · DOI
  123. Li, 2023, Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo, Expert Rev. Anti. Infect. Ther., 21, 1259, 10.1080/14787210.2023.2270160 · DOI
  124. Sun, 2015, Tetracyclines downregulate the production of LPS-induced cytokines and chemokines in THP-1 cells via ERK, p38, and nuclear factor-κB signaling pathways, Biochem. Biophys. Rep., 4, 397
  125. Peukert, 2021, Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury, Am. J. Respir. Crit. Care Med., 204, 53, 10.1164/rccm.202005-1916OC · DOI
  126. Dikshit, 2018, NLRP3 inflammasome pathway has a critical role in the host immunity against clinically relevant Acinetobacter baumannii pulmonary infection, Mucosal. Immunol., 11, 257, 10.1038/mi.2017.50 · DOI
  127. Yagnik, 2013, Tigecycline prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells, Toxicol. In Vitro, 27, 686, 10.1016/j.tiv.2012.11.015 · DOI
  128. Cockeran, 2012, Calcium-dependent potentiation of the pro-inflammatory functions of human neutrophils by tigecycline in vitro, J. Antimicrob. Chemother., 67, 130, 10.1093/jac/dkr441 · DOI
  129. Elhayek, 2018, Immunomodulatory Effects of Tigecycline in Balb/C Mice, Acta Pharm., 68, 457, 10.2478/acph-2018-0040 · doi:10.2478/acph-2018-0040
  130. Bryant, 2022, Investigating the immunomodulatory activities of omadacycline, J. Antimicrob. Chemother., 78, 78, 10.1093/jac/dkac356 · DOI
  131. Sriskanthadevan, 2011, Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia, Cancer Cell, 20, 674, 10.1016/j.ccr.2011.10.015 · DOI · Paper page
  132. Dong, Z., Abbas, M.N., Kausar, S., Yang, J., Li, L., Tan, L., and Cui, H. (2019). Biological Functions and Molecular Mechanisms of Antibiotic Tigecycline in the Treatment of Cancers. Int. J. Mol. Sci., 20. · DOI · Paper page
  133. Xu, Z., Yan, Y., Li, Z., Qian, L., and Gong, Z. (2016). The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties. Front. Pharmacol., 7. · DOI
  134. Ruiz-Malagón, A.J., Hidalgo-García, L., Rodríguez-Sojo, M.J., Molina-Tijeras, J.A., García, F., Diez-Echave, P., Vezza, T., Becerra, P., Marchal, J.A., and Redondo-Cerezo, E. (2023). Tigecycline reduces tumorigenesis in colorectal cancer via inhibition of cell proliferation and modulation of immune response. Biomed. Pharmacother., 163. · DOI
  135. Lu, 2017, Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia, J. Exp. Clin. Cancer Res., 36, 43, 10.1186/s13046-017-0512-6 · DOI
  136. Tan, 2017, Antibiotic tigecycline enhances cisplatin activity against human hepatocellular carcinoma through inducing mitochondrial dysfunction and oxidative damage, Biochem. Biophys. Res. Commun., 483, 17, 10.1016/j.bbrc.2017.01.021 · DOI
  137. Hu, 2019, Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance, Biochem. Biophys. Res. Commun., 509, 373, 10.1016/j.bbrc.2018.12.127 · DOI
  138. Yang, 2016, Tigecycline inhibits glioma growth by regulating miRNA-199b-5p-HES1-AKT pathway, Mol. Cancer Ther., 15, 421, 10.1158/1535-7163.MCT-15-0709 · DOI
  139. Zhong, 2016, Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo, Tumour. Biol., 37, 7615, 10.1007/s13277-015-4613-6 · DOI
  140. Xiong, 2018, Tigecycline as a dual inhibitor of retinoblastoma and angiogenesis via inducing mitochondrial dysfunctions and oxidative damage, Sci. Rep., 8, 11747, 10.1038/s41598-018-29938-x · DOI
  141. Jabarin, A., Shtar, G., Feinshtein, V., Mazuz, E., Shapira, B., Ben-Shabat, S., and Rokach, L. (2024). Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: Insights from a molecular-based deep learning model. Brief. Bioinform., 25. · DOI
  142. Rolston, 2023, In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer, JAC Antimicrob. Resist., 5, dlad020, 10.1093/jacamr/dlad020 · DOI
  143. Tao, R.E., Prajapati, S., Pixley, J.N., Grada, A., and Feldman, S.R. (2023). Oral Tetracycline-Class Drugs in Dermatology: Impact of Food Intake on Absorption and Efficacy. Antibiotics, 12. · DOI
  144. Opal, 2019, An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic, Clin. Infect. Dis., 69, S40, 10.1093/cid/ciz398 · doi:10.1093/cid/ciz398
  145. Wang, 2021, Acute pancreatitis caused by tigecycline: A case report and literature review, Medicine, 100, e28245, 10.1097/MD.0000000000028245 · doi:10.1097/md.0000000000028245
  146. Eljaaly, 2023, Long-term gastrointestinal adverse effects of doxycycline, J. Infect. Dev. Ctries., 17, 281, 10.3855/jidc.16677 · doi:10.3855/jidc.16677
  147. Rogers, 2004, Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity, Int. J. Dermatol., 43, 709, 10.1111/j.1365-4632.2004.02108.x · DOI · Paper page
  148. Rusu, A., and Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics, 13. · DOI · Paper page
  149. Lan, 2019, The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials, Medicine, 98, e18426, 10.1097/MD.0000000000018426 · doi:10.1097/md.0000000000018426
  150. Tanaka, 2016, In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline, Antimicrob. Agents Chemother., 60, 5247, 10.1128/AAC.00320-16 · doi:10.1128/aac.00320-16
  151. Kadoyama, 2012, Adverse event profile of tigecycline: Data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system, Biol. Pharm. Bull., 35, 967, 10.1248/bpb.35.967 · DOI
  152. Zhu, 2023, Clinical Manifestations and Risk Factors of Tigecycline-Associated Thrombocytopenia, Infect. Drug Resist., 16, 6225, 10.2147/IDR.S426259 · DOI
  153. Durães, F., and Sousa, E. (2019). Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals, 12. · DOI
  154. Leng, 2019, A Retrospective Analysis of the Effect of Tigecycline on Coagulation Function, Chem. Pharm. Bull., 67, 258, 10.1248/cpb.c18-00844 · doi:10.1248/cpb.c18-00844
  155. Ray, 2020, Tigecycline-Induced Severe Hypoglycemia in a Non-Diabetic Individual: A Case Report and Brief Review of Tigecycline-Induced Severe Hypoglycemia, Am. J. Case Rep., 21, e924556, 10.12659/AJCR.924556 · DOI
  156. Hakeam, 2024, Tigecycline and Hypoglycemia, When and How?, J. Pharm. Technol., 40, 37, 10.1177/87551225231211737 · DOI
  157. Prasad, 2012, Excess deaths associated with tigecycline after approval based on noninferiority trials, Clin. Infect. Dis., 54, 1699, 10.1093/cid/cis270 · DOI · Paper page
  158. McGovern, 2013, All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials, Int. J. Antimicrob. Agents, 41, 463, 10.1016/j.ijantimicag.2013.01.020 · DOI

Cited by

See all 64

Metadata

Authors
Kounatidis, D., Dalamaga, M., Grivakou, E., Karampela, I., Koufopoulos, P., Dalopoulos, V., Adamidis, N., Mylona, E., Kaziani, A., & Vallianou, N. G.
Venue
Biomolecules
Publisher
MDPI AG
Published
2024-06-30
Volume
14
Issue
7
Pages
783
ISSN
2218-273X
Cited by
64
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential. https://app.cochat.ai/papers/10.3390/biom14070783
The paper
Kounatidis, D., Dalamaga, M., Grivakou, E., Karampela, I., Koufopoulos, P., Dalopoulos, V., Adamidis, N., Mylona, E., Kaziani, A., & Vallianou, N. G. (2024). Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential. Biomolecules. https://doi.org/10.3390/biom14070783

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.